{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:11:16Z","timestamp":1770819076953,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41386-021-01142-y","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T15:03:05Z","timestamp":1629126185000},"page":"2228-2229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter"],"prefix":"10.1038","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-8754","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raye Z.","family":"Litten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"1142_CR1","doi-asserted-by":"publisher","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","volume":"5","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5:eaax4043.","journal-title":"Sci Adv"},{"key":"1142_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/acer.14233","volume":"44","author":"RZ Litten","year":"2020","unstructured":"Litten RZ, Falk DE, Ryan ML, Fertig J, Lorenzo L. Five priority areas for improving medications development for alcohol use disorder and promoting their routine use in clinical practice. Alcohol Clin Exp Res. 2020;44:23\u201335.","journal-title":"Alcohol Clin Exp Res"},{"key":"1142_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40263-018-0596-3","volume":"33","author":"P Maccioni","year":"2019","unstructured":"Maccioni P, Colombo G. Potential of GABAB receptor positive allosteric modulators in the treatment of alcohol use disorder. CNS Drugs. 2019;33:107\u201323.","journal-title":"CNS Drugs"},{"key":"1142_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915\u201322.","journal-title":"Lancet"},{"key":"1142_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34:1849\u201357.","journal-title":"Alcohol Clin Exp Res"},{"key":"1142_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/187152710790966614","volume":"9","author":"L Leggio","year":"2010","unstructured":"Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9:33\u201344.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1142_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","volume":"5","author":"R Agabio","year":"2018","unstructured":"Agabio R, Sinclair JM, Addolorato G, Aubin HJ, Beraha EM, Caputo F, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 2018;5:957\u201360.","journal-title":"Lancet Psychiatry"},{"key":"1142_CR8","doi-asserted-by":"publisher","unstructured":"Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: A dose-response, randomized, controlled trial. Neuropsychopharmacology 2021; https:\/\/doi.org\/10.1038\/s41386-021-01055-w.","DOI":"10.1038\/s41386-021-01055-w"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01142-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T08:10:15Z","timestamp":1636531815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01142-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":8,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1038\/s41386-021-01142-y","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}